SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Nome Químico: 2-[[3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzoimidazole sodium salt
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Sorrisos: O=S(C1=NC2=CC=CC=C2[N-]1)CC3=NC=CC(OCC(F)(F)F)=C3C.[Na+]
Lansoprazole Sodium is chemically 2-[[3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzoimidazole sodium salt. Lansoprazole Sodium is supplied with detailed characterization data compliant with regulatory guideline. Lansoprazole Sodium can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Lansoprazole.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Analytical Quality by Design (AQbD)-oriented RPUFLC method for quantification of lansoprazole with superior method robustness
Sagar Suman Panda, Venkata Varaha Ravi Kumar Bera, Sarwar Beg & Omkar Mandal
Journal of Liquid Chromatography & Related Technologies Volume 40, 2017 - Issue 9 Pages 479-485
Identification, isolation and characterization of potential degradation product in lansoprazole drug substance
K.Ramulu1 , B.M. Rao2* and N.Someswara Rao
Rasayan J. Chem. Vol. 6 | No.4 | 274 - 283 | October- December| 2013
Development and validation of an enantioselective and chemoselective HPLC method using a Chiralpak IA column to simultaneously quantify (R)-(+)- and (S)-(−)-lansoprazole enantiomers and related impurities
Roberto Cirilli, Rosella Ferretti ∗, Bruno Gallinella, Luciana Turchetto, Leo Zanitti, Francesco La Torre
Journal of Pharmaceutical and Biomedical Analysis 50 (2009) 9–14